Cavinalton 5mg Gedeon medicine reduces mental symptoms (2 blisters x 25 tablets)

Dosage form Box of 2 blisters x 25 tablets
Specifications Vinpocetine
Ingredient Gedeon

Ingredient

Composition information	Content
Vinpocetine	5mg

Uses

indications

Cavinalon 5 mg medicine is used to:

Reduce the mental symptoms of intellectual dementia due to circuit causes.

Pharmacology

Vinpocetine is a compound with a complex impact, which has a favorable impact on brain metabolism and blood circulation, as well as up blood toxicity of blood.

Vinpocetine has a nerve protection effect

It neutralizes the toxic effects of cell reactions due to stimulating amino acids. Vinpocetine inhibits Na+ and Ca ++ channels depending on the voltage as well as NMDA and AMPA receptors. Vinpocetine increases the mental protection of adenosin.

Vinpocetine stimulates brain metabolism

Vinpocetine helps brain tissue to increase and use oxygen and glucose, increase tolerance with oxygen deficiency of brain cells, improve glucose transport - the most unique source of energy of the brain - through the bloodstream barrier; The direction of the metabolism of glucose to the aerobic cycle is more favorable in terms of energy.

Vinpocetine selectively inhibits CGMP enzyme - Phosphodiesterase (PDE) depends on Ca ++ - Calmodulin; Increase the Camp and CGMP content of the brain. Vinpocetine increases ATP concentration and ATP/AMP ratio; increase the rotation of norepinephrin and serotonin of the brain; stimulating the noradrenergic system upwards; antioxidant activity; As a result, Vinpocetine has a brain protection effect.

Vinpocetine improves microcirculation

Vinpocetine inhibits platelet gathering; reduce the increase in pathological blood viscosity; increase red blood cell deformation and inhibit the acquisition of adenosin of Hong Cau; Increase oxygen into brain tissue by reducing oxygen properties with red blood cells.

Vinpocetine increases selectively with cerebral blood circulation

Vinpocetine causes the heart to increase blood pumping to the brain; Reducing brain -resistant resistance without affecting the parameters of the Week completely body (blood pressure, cardiac supply, heart rate, total peripheral resistance); Does not cause blood appropriation.

Moreover, while taking the drug, Vinpocetine increases blood supply to the brain area damaged (but has not been necrotic) due to local anemia that is less irrigated (inversely acting in blood appropriation).

Pharmacokinetics

absorption

Vinpocetine is quickly absorbed, the peak concentration in plasma reaches 1 hour after drinking. The main absorption point is the nearby side of the digestive system. This compound is not metabolized when passing through the intestinal wall.

Distribution

In oral medications in rats using radioactive isotopes, Vinpocetine has been detected with high concentrations in the liver and the digestive system. The maximum concentration in tissue can measure 2-4 hours after drinking.

Radioactive concentration measured in the brain is not higher than the concentration measured in the blood. In humans: Mounting with protein is 66%. Vinpocetine's absolute oral bioavailability is 7%. The distribution volume is 246.7 + 88.5 l, indicating a significant link to tissue. Vinpocetine clearance value (66.7 l/hour) exceeds the plasma value of the liver (50 l/hour), indicating the metabolism of the liver.

Elimination

While taking oral doses repeated with 5 mg and 10 mg doses, Vinpocetine shows linear dynamics; Plasma concentration in equilibrium state is 1.2 ± 0.27 ng/ml and 2.1 ± 0.33 ng/ml, respectively. The sale time in humans is 4.83 ± 1.29 hours. In studies conducted with radioactive active ingredients, it is found that the excretion path is through urine and feces at the ratio of 60/40.

Most radioactive substances are derived from mice and dogs, but have not been significantly confirmed by the intestinal circulation. Apovincamic acid is eliminated by the kidneys by simple glomerular filtration, the sale time depends on the dosage and the route of Vinpocetine.

Metabolism

The main metabolites of Vinpocetine are ApovinCaminic acid (AVA), created in humans 25-30%. After drinking, the area under the curve of AVA is twice as large as the intravenous injection indicates the AVA production in the first transformation phase.

Other metabolites have been qualified as hydroxyvinpocetine, hydroxy - ava, dihydroxy - ava glycinat and their complex substances with glucuronid and/or sulphat. In the research species, the amount of Vinpocetine was eliminated in the form of unprovered only a few percent of the dose.

The favorable and important feature of Vinpocetine is that it does not need to adjust the dose in patients with kidney and liver because its metabolism does not accumulate. There is no need to adjust the dose for patients with renal and liver impairment. The daily dose is from 1 to 2 Cavinalton 5 mg x 3 times (15 mg - 30 mg daily) or 1 Cavinalton x 3 times.

Changes of pharmacokinetic properties under special conditions (for example, age, accompanying disease).

Because Vinpocetine is indicated mainly to treat elderly patients, changing the dynamics of the drug - reduced absorption, distribution and transformation, reduced elimination - known, it is important to conduct dynamic studies in this age group, especially when taking long -term drugs. Research results show that Vinpocetine kinetics in the elderly are not big compared to young people, not increasing accumulation.

In the case of liver and kidney dysfunction, the usual dose may still be used because Vinpocetine does not accumulate even in these patients, allowing long -term treatment.

Before taking Cavinalton 5mg Gedeon medicine reduces mental symptoms (2 blisters x 25 tablets)

How to use

take the tablet with a glass of water. Take medicine after meals.

Dosage

must take the drug in accordance with the doctor's instructions. If there is something unclear, ask your doctor or pharmacist for instructions.

No dose adjustments for patients with renal impairment, liver failure.

The usual daily dose is 3 times, each time 2 Cavavinton 5 mg (30 mg per day).

If you find the effect of the drug is too strong or too weak for you, report to your doctor or pharmacist.What to do when overdose?

According to the literature, long -term use of daily daily dose 60 mg is still safe; Even after using a single dose of 360 mg of Vinpocetine, there is no significant heart effect on clinical and other adverse effects.

What to do when you forget 1 dose? Continue to take the next dose as usual.

Side Effects

Like other drugs, Caviton may have unwanted effects even though not all users encounter.

Less: nausea, dry mouth, abdominal discomfort, hypotension, headache, hypercholesterol, dizziness.

Rare: Platelet reduction, leukopenia, abnormal heartbeat (tachycardia or slow heartbeat), extra systolic, broken chest drum, myocardial ischemia, myocardial infarction, angina, sleep disorders (sleeping, insomnia), restlessness, excitement, dizziness, dizziness, stunning feeling, slightly paralysis on one side of the person, loss of memory, vomiting, vomiting, vomiting, hearing loss, hearing loss, hearing loss, vomiting, tinnamon weakness, fatigue, hot sensation, hypertension, hyperkemia (triglycerid), increased or decreased leukemia, abnormal liver enzymes, reducing appetite, diabetes, itching, increased sweat, urticaria, rash, rash, thrombophlebitis, electrocardiograms (short st and blushing.

Very rare: Anemia, red blood cells, hypersensitivity, refreshing mood, depression, tremor, convulsions, conjunctiva conjunctiva, arrhythmia, vibration, oscillating blood pressure, difficulty swallowing, stomatitis, dermatitis, discomfort in the chest, lower body heat, increased leukocyt cells, reducing red blood cells, reducing thrombin time, weight gain.

If there is any unwanted effect mentioned above becomes worse, or if you have any other side effects not listed in this user manual, please notify your doctor or pharmacist.

Warnings

This drug is only used by a doctor. Before using the drug, you need to read the user manual carefully and refer to the information below.

Contraindicated

Cavinalon 5 mg drug is contraindicated in the following cases:

Hypersensitivity (allergies) with Vinpocetine or any other ingredient of the drug.

Pregnancy or lactation.

Children (due to lack of clinical data).

Be cautious when using

Cavinalon 5 mg must be used according to the diagnosis for each patient:

In case the patient with heart disease (heart dysfunction, electrocardiogram deviation): recommendations of electrocardiogram control in case of prolonged QT interval or simultaneous use with another drug that extends the QT range.

Must inform the doctor about the existing condition.

Lactose -intolered people (milk sugar), need to know that each Cavanton tablet contains 140 mg of lactose.

The ability to drive and operate machinery

There is no data on the effect of the drug on the ability to drive and operate machinery.

The unwanted effect of the drug can most affect the ability to drive or operate the machine is headache, dizziness, dizziness, sleeping, abnormal heart rate, mental mental reaction, agitation and restlessness. These effects sometimes or rarely occur. Patients with these unwanted effects should consult a doctor before taking the drug.

During pregnancy and lactation

Do not take this medication during pregnancy or lactation.

Drug interaction

in clinical studies when using Vinpocetine with beta -blockers such as chloranolol and pindolol, with Clopamid, Glibenclamid, Digoxin, Acenocoumarol or with hydrochlorothiazid without drug interactions. When using Vinpocetine with Alphamethyl Dopa, he had a mild auxiliary effect, so blood pressure should be controlled regularly while combining drugs.

Although clinical research data does not show, it must be cautious in case of coordination with drugs that affect the central nervous system, as well as when coordinating with anti -arrhyths and anticoagulant drugs.

Storage

Store drugs at temperatures from 15 ° C - 30 ° C. Keep the drug in the carton box to avoid light.

To be out of reach of children.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.